Plasma therapy developers jump as U.S. authorizes plasma treatment for COVID-19
24/08/2020 17:47
(Updates)
** Shares of blood-plasma product developers jump after the
U.S. FDA allows use of convalescent plasma for treating COVID-19
** The agency on Sunday authorized the use of blood plasma
from COVID-19 recovered patients as a treatment for the illness,
a day after President Donald Trump blamed the agency for
impeding the rollout of coronavirus vaccines and therapeutics
for political reasons urn:newsml:reuters.com:*:nL1N2FP0CD urn:newsml:reuters.com:*:nL1N2FP0B8
** Shares of ADMA Biologics Inc ADMA.O and U.S.-listed
shares of Israel-based Kamada Ltd KMDA.O rise ~13%
** With the issuance of an emergency use authorization,
companies in the space stand to benefit, including ADMA, given
its unique expertise in antibody therapies in treating
respiratory viral infections - Maxim Group
** XBiotech Inc XBIT.O says its COVID-19 test to detect
antibodies in patients' blood can now be used after U.S. FDA's
emergency approval for blood plasma as a potential treatment for
the illness; shares jump ~10% urn:newsml:reuters.com:*:nGNE1XP88n
(Reporting by Trisha Roy and Manojna Maddipatla in Bengaluru)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))